晚期 HER2 阴性乳腺癌患者瘤内注射 talimogene laherparepvec(T-VEC)联合化疗或内分泌治疗的 Ib 期研究 Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-n PubMed 2025/11/21 发表NPJ Breast CancerQ1 · IF 8.4(JCR 2025) 靶点:HER2技术:TIL技术:溶瘤病毒乳腺癌地区:美国